Skip to main content

Table 1 Baseline demographic characteristics and clinical features

From: Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Baseline parameter (mean ± SD)

Canocapavir

Placebo n = 6

50 mg n = 8

100 mg n = 8

200 mg n = 8

Age, years

36.9 (9.08)

36.9 (6.15)

41.8 (10.91)

47.7 (10.86)

Sex (male/female)

6/2

3/5

6/2

4/2

Ethnicity (Han/other)

8/0

7/1

8/0

6/0

Weight (kg)

67.60 (10.645)

54.20 (7.648)

71.43 (6.443)

69.48 (7.51)

HBV DNA (log10 IU/mL)

6.68 (1.64)

7.16 (1.52)

6.04 (1.84)

6.42 (2.07)

HBV pgRNA (log10 copies/mL)

6.04 (1.66)

5.60 (1.68)

5.10 (2.00)

5.14 (2.79)

HBcrAg (log10 Ku/mL)

3.98 (2.16)

4.38 (1.86)

3.29 (2.04)

2.99 (2.45)

HBsAg (log10 IU/mL)

4.23 (0.62)

4.10 (1.00)

3.97 (0.75)

3.79 (1.17)

HBeAg (log10 PEI-U/mL)

3.06 (0.09)

3.09 (0.22)

2.05 (1.42)

2.77 (0.43)

HBeAg (positive/negative)

5/3

5/3

4/4

3/3

Fibroscan (kPa)

5.05 (0.42)

5.41 (2.18)

5.54 (1.10)

5.05 (1.01)

ALT (U/L)

30.89 (18.95)

46.65 (42.72)

41.13 (14.62)

35.98 (19.16)

AST (U/L)

27.09 (9.48)

52.61 (46.25)

33.06 (9.97)

30.75 (8.16)

genotype

B = 3; C = 5

B = 2; C = 6

B = 1; C = 7

B = 3; C = 3

  1. BMI body mass index, HBV hepatitis B virus, HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, HBeAg hepatitis B e antigen, HBcrAg hepatitis B core antigen, pgRNA pregenomic RNA